Better treatment for common childhood brain cancer

June 26, 2012
Pediatric Cancer Genome Project researchers identified potential drug targets for medulloblastoma. Credit: St. Jude Children’s Research Hospital

Children diagnosed with the most common paediatric malignant brain cancer, medulloblastoma, will benefit from more targeted treatment following the identification of genetic mutations in the cancer.

The international research findings published in Nature may lead to the development of and better outcomes for patients, says Richard Cohn, Conjoint Associate Professor at the University of New South Wales.

A specialist at the Centre for Children’s Cancer and Blood Disorders, Associate Professor Cohn contributed to the research led by a team at St. Jude Comprehensive Cancer Center in the United States.

“The discovery of tumour-specific gene alterations linked to subtypes of provides important insights into the development of the cancer and highlights targets for new treatment approaches,” he said.

The findings were a direct result of collaboration between six children’s oncology centres internationally, which pooled patient specimens and information.

“Now that we know about these mutations, the hope is we’ll be able to develop new drugs, or utilise existing drugs not currently used to treat this disease, to specifically attack the molecular abnormality,” Associate Professor Cohn said.

“Ideally this will lead to better outcomes for patients and better cure rates and the ability to achieve that with fewer side effects.”

Explore further: Researchers find simple reason why some children die despite aggressive modern therapy for brain cancer

Related Stories

Recommended for you

Ancient stress response provides clues to cancer resistance

April 25, 2017

Cancer is often able to craftily outwit the best techniques modern medicine has developed to treat it. In an attempt to understand and combat cancer's vaunted prowess, an unusual collaboration between physicists and a leading ...

Studying a catalyst for blood cancers

April 25, 2017

Imagine this scenario on a highway: A driver starts to make a sudden lane change but realizes his mistake and quickly veers back, too late. Other motorists have already reacted and, in some cases, collide. Meanwhile, the ...

Savior of T-cells may be enemy of liver immune cells

April 24, 2017

Researchers at Houston Methodist demonstrated that a surface protein called OX40, responsible for keeping one type of immune system cell alive, can trigger the death of liver immune cells, in turn starting a chain reaction ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.